Phalguni Deswal

CAR T enters a new era of in vivo reprogramming of T cells Vyriad's Luke Russell explores the technical and economic promise of in vivo CAR T-cell therapies.

The CAR T field is shifting to in vivo platforms that aim to make powerful cell therapies simpler, cheaper, and more accessible. Insights from Vyriad's Luke Russell. #CARTcell #immunotherapy #invivo #biotech #Vyriad #oncology #celltherpay

Building resilient pharmaceutical supply chains in an era of disruption Kum Ming Woo advises prioritizing supplier quality & availability over cost, emphasizing geographic diversification and stage-appropriate strategies.

Cost shouldn’t be your first question in pharma supply chains, says Vector Labs’ Kum Ming Woo. Prioritize quality & availability, diversify geographically, and adopt stage-appropriate strategies.

#Interview #Expert #Pharma #SupplyChain #Biotech #Resilience #DrugDevelopment

Rapid Nexus study challenges neuropathy as the point of no return New peer-reviewed research indicates nerve function is key to healing tissue once considered unsalvageable.

New study from Rapid Nexus challenges old view of nerve damage. Research shows targeting neuropathy can heal tissue once considered unsalvageable, helping patients avoid amputation.
#News #Diabetes #WoundCare #Neuropathy #MedicalInnovation #Research

Hospital of 2026: Local LLMs and AI Are Redefining Healthcare myTomorrow’s Danny den Hamer identifies two trends for 2026: hospitals adopting local AI/trusted partners, and a rise in certified AI medical devices.

In 2026, hospitals will split between running their own local AI and forming trusted partnerships, while certified AI medical devices gain major trust, says myTomorrow's Danny den Hamer.
#AIinHealthcare #HealthTech2026 #SaMD #LLM #DigitalHealth #Tends

Arkin Bio Ventures III: $100 million fund for transformative therapies Fund lead, Dr. Pini Orbach, talks about the fund targeting oncology, immunology, inflammation, rare diseases, and their aim to be an active partner from day one.

Arkin Capital launches $100M Arkin Bio Ventures III to back transformative biotech companies. The fund takes a hands-on, science-driven approach as an active partner from day one.
#News #Interview #Biotech #VentureCapital #Therapeutics #DrugDiscovery

Becton Dickinson and ten23 partner on wearable injector supply Partnership will support the supply for Becton, Dickinson and Company's self-administered therapies with a ready-to-use, scalable platform.

ten23 health & BD partner to enable supply chain readiness for the BD Libertas wearable injector. The full-service solution aims to speed development of large-volume, self-administered therapies.

#News #SupplyChain #WearableInjector #Biotech #Pharma #DrugDelivery #Partnership

Genesipre’s rare disease therapy gets orphan drug status in the US and Europe The gene therapy is being developed to treat a rare pediatric metabolic disease, methylmalonic acidemia (MMA).

Genesipre’s gene therapy GENE202 has received Orphan Drug Designation for methylmalonic acidemia (MMA), a rare pediatric disease.
#News #GeneTherapy #RareDisease #OrphanDrug #MMA #Biotech

Boehringer picks AI imaging tech as co-primary endpoint for IPF trial Brainomix's e-Lung AI will provide quantitative imaging biomarkers as a co-primary endpoint in Boehringer Ingelheim's Phase III DROP-FPF study.

Brainomix's AI imaging tech will serve as a co-primary endpoint in Boehringer Ingelheim's Phase 3 DROP-FPF trial for pulmonary fibrosis—a first for ILD studies. #AI #News #ClinicalTrials #PulmonaryFibrosis #MedicalImaging #Brainomix

VCU researchers win $1.8 million US DoD grant for cancer therapy The US Department of Defense (DoD) grant funds engineered NK cell therapy for resistant prostate cancer.

VCU researchers awarded $1.8M DoD grant to develop a novel engineered NK cell therapy targeting incurable, advanced prostate cancer (CRPC).
#News #ProstateCancer #Immunotherapy #CRPC #CellTherapy #NKcells #IL24 #DoDgrant

The New Gold Rush: High-stakes race for multi-cancer blood tests Abbott's $21 billion Exact Sciences buyout sets stage for high-stakes MCED battle, Elena Ming talks about the major players in the sector and hurdles.

Abbott’s $21B acquisition of Exact Sciences signals a new era in cancer detection. We analyze the high-stakes MCED market, pivotal FDA decisions, and the reimbursement battle ahead with Gabelli Funds’ Elena Meng.

#MCED #cancerscreening #Abbott #ExactSciences #healthcareinvesting #biotech

Stereotaxis MAGiC catheter cleared by FDA for robotic heart ablation The US FDA approves Stereotaxis' robotic magnetic navigation catheter for complex cardiac arrhythmia procedures.

FDA approves Stereotaxis MAGiC robotic ablation catheter. A breakthrough for treating complex heart arrhythmias with precise magnetic navigation.
#News #Stereotaxis #FDAapproval #cardiology #robotics #arrhythmia #healthtech

Examining the growing delays in clinical trial start-up ICON exec discusses the increasing timeframe from site selection to full activation, including the issues contributing to the delay and measures to address them.

Clinical trial start-up delays are rising due to complex protocols & contract bottlenecks. ICON survey data reveals 55% of sites take 5+ months to activate. Solutions require site-centricity & smarter tech.
#Interview #ClinicalTrials #StudyStartup #SiteCentricity #ICON #DrugDevelopment

Eisai subsidiary starts Phase III trial for Schizophrenia drug in Japan EA Pharma initiates a pivotal study of the novel glutamate modulator, evenamide, for treatment-resistant schizophrenia in Japan.

EA Pharma (Eisai) starts Phase III trial in Japan for evenamide, a novel glutamate modulator for schizophrenia.
The drug was licensed as part of a €117M deal with Newron Pharmaceuticals.

#News #Schizophrenia #ClinicalTrial #MentalHealth #Biotech #Eisai #Evenamide

Canopy raises $22 million for healthcare safety platform The Series B funding is expected to finance the expansion of Canopy’s connected safety platform across US health systems.

Canopy secures $22M Series B to expand its connected safety platform for combating workplace violence and modernize hospital operations with location intelligence.
#News #HealthTech #SeriesB #WorkplaceSafety #Innovation #LocationIntelligence

Endometriosis study uncovers molecular subgroups to guide trials Endogene.bio’s research reveals how single-cell analysis predicts drug efficacy, enabling targeted treatments for endometriosis subgroups.

New #research by endogene.bio reveals why #endometriosis treatments often fail. The study identifies molecular subgroups & predicts drug response, suggesting non-invasive monitoring via menstrual blood could guide precision therapy.
#News #WomensHealth #PrecisionMedicine #ClinicalTrials

ASH25: Gallop’s LYT-200 shows unprecedented survival in AML The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.

Gallop’s LYT-200 shows 13.2-month median survival in late-line AML at #ASH2025—far exceeding historic benchmarks. The anti-galectin-9 antibody combines strong efficacy with a clean safety profile.

#News #Leukemia #Oncology #Biotech #ClinicalTrials #AML

SweetBio’s honey-based bandage saving limbs and closing wounds The US-based company’s CEO talks about how novel biomaterial tackles the hidden crisis of chronic wounds, blending ancient remedies with modern science to prevent amputations.

Healing chronic wounds twice as fast? SweetBio’s honey-based biomaterial is tackling the hidden amputation crisis, blending ancient remedies with cutting-edge science. #News #WoundCare #Diabetes #MedTech #Innovation #Biomaterials #DiabeticFootUlcer

Old becomes New: CNS Pharma’s quest to tackle brain cancers CNS Pharmaceuticals’ CMO explains how they are re-engineering old chemotherapies to penetrate the brain, aiming for a breakthrough in treating aggressive glioblastoma.

CNS Pharmaceuticals re-engineers old chemotherapies to cross the blood-brain barrier, targeting aggressive glioblastoma. Dr. Sandra Silberman explains their "back to the future" strategy and two promising drugs. #BrainCancer #Glioblastoma #Biotech #Oncology #BloodBrainBarrier #CNSPharmaceuticals

Secura Bio’s Copiktra PTCL data shines at ASH 2025  The company’s exec talks about how new analyses bolster the case for Copiktra in tough-to-treat lymphomas, informing a pivotal Phase III trial strategy.

New data at #ASH2025 show Secure Bio's Copiktra's (duvelisib) consistent efficacy in heavily pretreated PTCL, with strong signal in AITL informing Phase 3 TERZO trial in nTFHL.
#news #interview #lymphoma #clinicaltrials #oncology

FoRx secures $50 million to advance PARG inhibitor Swiss biotech raises Series A financing to advance PARG inhibitor FORX-428, with initial clinical data expected in 2026.

FoRx Therapeutics raises $50M Series A to advance clinical trial of FORX-428, a PARG inhibitor for PARP-resistant cancers. Initial data expected mid-2026.
#News #Biotech #Funding #Oncology #ClinicalTrials #PARG

CTMC maps out plans to democratize cell therapy CTMC’s Amy Hay details a partnership model to share knowledge and expand cell therapy access worldwide, starting with Brazil.

CTMC’s global alliance partners with Brazil’s Einstein Hospital to democratize cell therapy. CTMC’s Amy Hay details a partnership model to share knowledge and expand cell therapy access worldwide.
#News #Interview #CellTherapy #GlobalHealth #MedicalInnovation

Milestone Pharma wins FDA nod for self-administered nasal spray for PSVT The at-home treatment is designed to manage acute symptomatic episodes outside of emergency healthcare settings.

FDA approves Cardamyst, the Milestone Pharmaceuticals’ self-administered nasal spray for PSVT. A rapid at-home treatment for sudden rapid heart episodes, available in 2026.
#News #PSVT #CARDAMYST #FDAapproval #HeartHealth #MedicalNews

Rapid Nexus charts a new path for chronic wounds Dr. Margaret Kalmeta, CEO of Rapid Nexus, discusses the first device cleared to treat the tissue around chronic wounds and the company’s pipeline.

Dr. Margaret Kalmeta, CEO of Rapid Nexus, discusses the first device cleared to treat the tissue around chronic wounds, aiming to prevent amputations. Read more for company's pipeline and future plans
#MedTech #WoundCare #FDA #Diabetes #Innovation #Interview #News

SABCS25: Agendia’s genomic testing guides breast cancer care  Agendia’s VP of clinical development notes that new FLEX study data show genomic signatures predict chemotherapy benefit, improving personalized treatment for early breast cancer.

New data from Agendia's FLEX study at #SABCS2025 shows genomic signatures like MammaPrint can guide chemo choices & identify benefit in elderly patients.
#news #breastcancer #precisionmedicine #realworldevidence

HeartBeam’s stock shows strong pulse after FDA clearance A cable-free, credit-card sized ECG device for at-home heart monitoring receives regulatory approval, paving the way for a 2026 launch.

HeartBeam receives FDA clearance for the first cable-free, at-home 12-lead ECG. This breakthrough allows for clinical-grade heart rhythm assessment anytime, anywhere. A major leap for remote cardiac care.
#New #HeartBeam #FDA #MedTech #Cardiology #DigitalHealth

AC Immune’s stock rises with positive Phase II data Interim Phase II data suggest its vaccine candidate may slow progression, a potential first in Parkinson's treatment.

AC Immune's Phase 2 vaccine for Parkinson’s shows first-ever signs of potentially slowing disease progression. 100% 100% responder rate for immunogenicity & stabilized biomarkers signal a promising step forward.
#News #Parkinsons #Biotech #ClinicalTrial #Neurodegenerative #ACI7104

VUGENE partners with Inotiv to power AI-driven drug discovery Lithuanian bioinformatics firm launches into pharmaceutical services via a strategic CRO collaboration aimed at accelerating multi-omics analysis.

VUGENE teams up with CRO Inotiv to accelerate AI-driven drug discovery through advanced multi-omics analysis. A key move into the pharmaceutical services market.

#News #AI #DrugDiscovery #MultiOmics #Bioinformatics #CRO #Biotech

Sanofi’s ASH 2025: Redefining rare blood disorder care Sanofi’s head of rare diseases, Jeff Schaffnit, outlines the company's dual approach: redefining hemophilia care and pioneering immune modulation for rare blood disorders.

Sanofi’s #ASH25 data highlight leadership in rare blood diseases, from multi-immune modulation with #BTKinhibitor Wayrilz to long-term hemophilia care with ALTUVIIIO. Transforming patient lives through science.
#News #Interview #RareDisease #Hemophilia #Immunoscience

Vyome’s stock rises on positive Phase II data for wound care drug Vyome's VT-1953 gel significantly reduced odor and pain in malignant fungating wounds, prompting plans for a pivotal Phase III study.

Vyome shares rise on positive Phase 2 data for its wound care gel VT-1953, showing significant reduction in odor & pain. Pivotal study targeted for 2026.
#News #Biotech #ClinicalTrial #Healthcare #WoundCare

ASH25: Tessera’s gene writing hits curative thresholds in sickle cell New preclinical data show Gene Writing tech exceeding key efficacy benchmarks for sickle cell disease and in vivo CAR-T generation.

Tessera Therapeutics' Gene Writing platform hits new preclinical milestones. Data shows edited stem cells exceed curative thresholds for sickle cell disease & successful in vivo generation of functional CAR-T cells.
#News #GeneWriting #SickleCellDisease #CAR_T #ASH2025 #Biotech